Compare FNKO & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNKO | FHTX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.3M | 323.4M |
| IPO Year | 2017 | 2020 |
| Metric | FNKO | FHTX |
|---|---|---|
| Price | $6.07 | $5.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $6.00 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 581.0K | 356.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $908,209,000.00 | $30,909,000.00 |
| Revenue This Year | $4.42 | $8.89 |
| Revenue Next Year | $6.50 | $20.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $2.22 | $3.27 |
| 52 Week High | $6.26 | $6.95 |
| Indicator | FNKO | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.17 | 52.40 |
| Support Level | $5.10 | $4.37 |
| Resistance Level | N/A | $5.53 |
| Average True Range (ATR) | 0.26 | 0.37 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 88.75 | 19.89 |
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.